# Losmapimod PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/losmapimod

> Losmapimod, sponsored by Fulcrum Therapeutics, Inc. (FULC): 1 recorded catalyst.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | losmapimod |
| Codes |  |
| Sponsor | Fulcrum Therapeutics, Inc. (FULC) https://sec-api.dev/companies/fulc/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### Sep 2024: topline data readout

- Status: completed, mixed. Date confidence: month. Stage: 3.
- First seen 2024-11-13, last confirmed 2026-07-30.
- SEC Form 10-Q (accession 0001193125-26-326098): "For example, we invested significant time and effort into developing losmapimod for facioscapulohumeral muscular dystrophy, or FSHD but did not demonstrate a statistically significant difference between losmapimod and placebo on the primary endpoint in the Phase 3 REACH trial, for which we announced topline data in September 2024, and we thereafter discontinued development." https://www.sec.gov/Archives/edgar/data/1680581/000119312526326098/fulc-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-178814): "For example, we invested significant time and effort into developing losmapimod for facioscapulohumeral muscular dystrophy, or FSHD but did not demonstrate a statistically significant difference between losmapimod and placebo on the primary endpoint in the Phase 3 REACH trial, for which we announced topline data in September 2024, and we thereafter discontinued development." https://www.sec.gov/Archives/edgar/data/1680581/000119312526178814/fulc-20260331.htm
- SEC Form 10-K (accession 0001193125-26-065197): "For example, we invested significant time and effort into developing losmapimod for facioscapulohumeral muscular dystrophy, or FSHD, but did not demonstrate a statistically significant difference between losmapimod and placebo on the primary endpoint in the Phase 3 REACH trial, for which we announced topline data in September 2024, and we thereafter discontinued development." https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm
- SEC Form 10-K (accession 0001193125-26-065197): "In September 2024, the Company announced topline data showing that it did not demonstrate a statistically significant difference between losmapimod and placebo on the primary endpoint in the Phase 3 REACH trial, and thereafter discontinued development." https://www.sec.gov/Archives/edgar/data/1680581/000119312526065197/fulc-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-254633): "In September 2024, the Company announced topline data showing that it did not demonstrate a statistically significant difference between losmapimod and placebo on the primary endpoint in the Phase 3 REACH trial, and thereafter discontinued development." https://www.sec.gov/Archives/edgar/data/1680581/000119312525254633/fulc-20250930.htm
- SEC Form 10-Q (accession 0001193125-25-254633): "For example, we invested significant time and effort into developing losmapimod for FSHD but did not demonstrate a statistically significant difference between losmapimod and placebo on the primary endpoint in the Phase 3 REACH trial, for which we announced topline data in September 2024 and thereafter discontinued development." https://www.sec.gov/Archives/edgar/data/1680581/000119312525254633/fulc-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-099407): "In September 2024, the Company announced topline data showing that it did not demonstrate a statistically significant difference between losmapimod and placebo on the primary endpoint in the Phase 3 REACH trial, and thereafter discontinued development." https://www.sec.gov/Archives/edgar/data/1680581/000095017025099407/fulc-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-099407): "For example, we invested significant time and effort into developing losmapimod for FSHD but did not demonstrate a statistically significant difference between losmapimod and placebo on the primary endpoint in the Phase 3 REACH trial, for which we announced topline data in September 2024 and thereafter discontinued development." https://www.sec.gov/Archives/edgar/data/1680581/000095017025099407/fulc-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-061442): "In September 2024, the Company announced topline data showing that it did not demonstrate a statistically significant difference between losmapimod and placebo on the primary endpoint in the Phase 3 REACH trial, and thereafter discontinued development." https://www.sec.gov/Archives/edgar/data/1680581/000095017025061442/fulc-20250331.htm
- SEC Form 10-Q (accession 0000950170-25-061442): "For example, we invested significant time and effort into developing losmapimod for FSHD but did not demonstrate a statistically significant difference between losmapimod and placebo on the primary endpoint in the Phase 3 REACH trial, for which we announced topline data in September 2024 and thereafter discontinued development." https://www.sec.gov/Archives/edgar/data/1680581/000095017025061442/fulc-20250331.htm
- SEC Form 10-K (accession 0000950170-25-026068): "For example, we invested significant time and effort into developing losmapimod for FSHD but did not demonstrate a statistically significant difference between losmapimod and placebo on the primary endpoint in the Phase 3 REACH trial, for which we announced topline data in September 2024 and thereafter discontinued development." https://www.sec.gov/Archives/edgar/data/1680581/000095017025026068/fulc-20241231.htm
- SEC Form 10-Q (accession 0000950170-24-125931): "For example, we invested significant time and effort into developing losmapimod for FSHD but did not demonstrate a statistically significant difference between losmapimod and placebo on the primary endpoint in the Phase 3 REACH trial, for which we announced topline data in September 2024." https://www.sec.gov/Archives/edgar/data/1680581/000095017024125931/fulc-20240930.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/losmapimod.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Losmapimod PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/losmapimod

```bibtex
@misc{secapidev_pdufa_losmapimod_20261116,
  title        = {Losmapimod PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/losmapimod}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_losmapimod_20261116","title":"Losmapimod PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/losmapimod","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
